arrow_back Back to App

Improved Access to Orphan Drugs: New Pricing Rules

This act aims to improve access to drugs for rare diseases, known as orphan drugs. These changes may affect the availability and cost of treatment for individuals with rare conditions, potentially accelerating the introduction of new therapies to the market.
Key points
Orphan drugs (for rare diseases) will have an extended exclusion period from the drug price negotiation program, potentially encouraging their production.
The definition of an orphan drug will be broadened to include drugs for one or more rare diseases, increasing the number of eligible therapies.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_946
Sponsor: Rep. Joyce, John [R-PA-13]
Process start date: 2025-02-04
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ORPHAN Cures Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_946.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-04.

What are the main provisions?

Key points include:

  • Orphan drugs (for rare diseases) will have an extended exclusion period from the drug price negotiation program, potentially encouraging their production.
  • The definition of an orphan drug will be broadened to include drugs for one or more rare diseases, increasing the number of eligible therapies.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Joyce, John [R-PA-13].

What is the latest detailed status?

The latest detailed status is: Sponsor introductory remarks on measure. (CR H535-536)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health